Meditrina Pharmaceuticals, Inc. Announces Exclusive Global Manufacturing Agreement With Pfizer CentreSource (PCS) for Femathina(TM) (MPI-674)

Thursday, September 20, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

ANN ARBOR, Mich., Sept. 19 Meditrina Pharmaceuticals,Inc., today announced that it is has completed a contract manufacturingagreement for drug product development and active pharmaceutical ingredient(API) supply with a unit of Pfizer CentreSource (PCS), a leading supplier ofAPIs and dosage form manufacturing, for the Company's lead product candidate,Femathina(TM) (MPI-674). Currently in phase II clinical trials, MPI-674 is anaromatase inhibitor that Meditrina is repurposing for the treatment of severalserious women's health conditions including endometrial thinning prior toendometrial ablations in premenopausal women with abnormal uterine bleeding(AUB).

"We are delighted to have such a skilled and reputable manufacturingpartner for MPI-674," said Holly Vene, COO and vice president, businessdevelopment, Meditrina Pharmaceuticals, Inc. "Securing a high-qualitycommercial supply chain partner has been a key focus of the organization andrepresents an important milestone in advancing our product developmentprogram."

"We look forward to working with Meditrina, a respected and innovativecompany that is also located in Michigan, a state in which PCS has deeproots," commented Michael J. Kosko, president, Pfizer CentreSource. "And weare delighted to be able to contribute our development and manufacturingexpertise to the supply of this product."

Terms of the agreement were not disclosed.

About MPI-674

MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-yearchronic safety and tolerability profile. AIs are a class of drugs that reducethe amount of estrogen circulating in the body by binding to and inhibitingthe enzyme aromatase, which is responsible for converting certain hormones toestrogen. AIs are currently used for the chronic treatment of estrogen-dependent tumors in postmenopausal women and are being investigated in avariety of women's health conditions. Meditrina holds the exclusive worldwiderights to patent applications covering the use of AIs in gynecologicindications, including for endometrial thinning prior to hysteroscopicprocedures.

About Meditrina Pharmaceuticals, Inc.

Meditrina Pharmaceuticals, Inc. is a clinical-stage, specialtypharmaceutical company focused on developing and commercializing innovativetherapies that treat women's reproductive system disorders, with an initialfocus on gynecologic and aromatase-mediated conditions with serious unmetmedical needs. By identifying, leveraging and repurposing marketed productsand product candidates at advanced stages of development, Meditrina's noveltherapies have the potential to significantly alter the way these women'shealth conditions are treated. For more information about MeditrinaPharmaceuticals, please visit

About Pfizer CentreSource

Pfizer CentreSource (PCS) is a separate operating unit within Pfizer, theworld's leading research-based pharmaceutical company, which has extensivecapabilities and experience in active pharmaceutical ingredient and dosageform manufacturing. A globally networked business, PCS markets activepharmaceutical ingredients (APIs), fine chemical intermediates, finisheddosage forms and provides analytical and regulatory support. For moreinformation, contact Pfizer CentreSource at 269-833-5844 or

Meditrina Pharmaceuticals, Inc. Forward-Looking Statement Disclaimer

This announcement may contain, in addition to historical information,certain forward-looking statements that involve risks and uncertainties. Suchstatements reflect management's current views and are based on certainassumptions. Actual results could differ materially from those currentlyanticipated as a result of a number of factors. The company is developingseveral products for potential future marketing. There can be no assurancethat such development efforts

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store